DRMAW Projected Dividend Yield
Wt/Dermata Therapeutics Inc ( NASDAQ : DRMAW )Dermata Therapeutics, Inc. is a late-stage medical dermatology company. Co. is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a U.S. market size of approximately 50 million patients. 20 YEAR PERFORMANCE RESULTS |
DRMAW Dividend History Detail DRMAW Dividend News DRMAW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |